Inflammation signature scores

The tumor inflammation signature score (TIS) was also calculated.Preliminary Phase 1/2 biomarker data from paired tumor biopsies include the following: Immunohistochemistry for CD8 and PD-L1 (n=30) indicated robust and increased infiltration of CD8+ T cells and PD-L1 expression, both after combined treatment with RP1 and nivolumab and after single agent RP2 across different tumor types, and including reversal of T cell exclusion following prior combined treatment with ipilimumab and nivolumab in melanoma. Consistent with the pre-clinical data, preliminary clinical biomarker data indicate substantial increase in CD8 T cell infiltration and PD-L1 expression, as well as increased TIS score in the majority of patients treated with RP2 alone or RP1 and nivolumab combination. Particularly marked effects were seen in some patients with clinical responses which occurred independent of both baseline PD-L1 and prior anti-PD1 therapy status, which suggests potential broad utility of the RP1/2 treatment approach in igniting an anti-tumor immune response. Tumor mutation burden analysis and T cell receptor sequencing are currently underway and further updates of the dataset will be presented.
Combination therapy • Late-breaking abstract • Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CSF2 (Colony stimulating factor 2) • CD27
PD-L1 expression • CSF2 expression • Inflammation signature scores • CTLA4 expression
PD-L1 IHC 28-8 pharmDx
Opdivo (nivolumab) • Yervoy (ipilimumab) • RP2 • vusolimogene oderparepvec (RP1)
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our